acthar, epipen and even oxycontin have $10 competitors which have been shown to be at least as good for their use cases. The belief that they do not (which is e

acthar, epipen and even oxycontin have $10 competitors which have been shown to be at least as good for their use cases. The belief that they do not (which is encoded into some medical recommendations and public policy) is a testament to how effective that marketing is. In fact, oxycontins claim to fame is its uniqueness in how long it acts for and therefore reduced addiction potential, which does not actually work this way. The “non competition” belief is itself a marketed reality for many drugs.